JP2024542978A - 抗ｃｄ４７抗体及びその使用方法 - Google Patents

抗ｃｄ４７抗体及びその使用方法 Download PDF

Info

Publication number
JP2024542978A
JP2024542978A JP2024524985A JP2024524985A JP2024542978A JP 2024542978 A JP2024542978 A JP 2024542978A JP 2024524985 A JP2024524985 A JP 2024524985A JP 2024524985 A JP2024524985 A JP 2024524985A JP 2024542978 A JP2024542978 A JP 2024542978A
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
cdr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024524985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542978A5 (https=
Inventor
ファンヨン トゥー，
ピーター ペイチー ルオ，
ヤン リー，
ピン ツァイ，
チエンフォン シー，
チアンチュン シュイ，
アーロン グエン，
ソンマオ チョン，
ギジョン リュウ，
チョンシー タイ，
Original Assignee
アダジーン プライベート リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アダジーン プライベート リミテッド filed Critical アダジーン プライベート リミテッド
Publication of JP2024542978A publication Critical patent/JP2024542978A/ja
Publication of JP2024542978A5 publication Critical patent/JP2024542978A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024524985A 2021-10-27 2022-10-27 抗ｃｄ４７抗体及びその使用方法 Pending JP2024542978A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/126597 2021-10-27
PCT/CN2021/126597 WO2023070353A1 (en) 2021-10-27 2021-10-27 Anti-cd47 antibodies and methods of use thereof
PCT/CN2022/127875 WO2023072177A1 (en) 2021-10-27 2022-10-27 Anti-cd47 antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024542978A true JP2024542978A (ja) 2024-11-19
JP2024542978A5 JP2024542978A5 (https=) 2025-10-29

Family

ID=86160307

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024524985A Pending JP2024542978A (ja) 2021-10-27 2022-10-27 抗ｃｄ４７抗体及びその使用方法

Country Status (9)

Country Link
US (1) US20240417463A1 (https=)
EP (1) EP4423138A4 (https=)
JP (1) JP2024542978A (https=)
KR (1) KR20240111823A (https=)
CN (1) CN118434769A (https=)
AU (1) AU2022376756A1 (https=)
CA (1) CA3235611A1 (https=)
TW (1) TW202334216A (https=)
WO (2) WO2023070353A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121752591A (zh) 2023-07-03 2026-03-27 新免疫技术有限公司 异源二聚体Fc分子及其用途
WO2025019791A1 (en) * 2023-07-20 2025-01-23 Exelixis, Inc. Activatable ror binding agents and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2771336C (en) * 2009-09-15 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
KR20160018579A (ko) * 2013-06-04 2016-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항체를 접합하기 위한 조성물 및 방법
CN111212852A (zh) * 2017-08-18 2020-05-29 超人肆有限公司 结合剂
SG11202004864TA (en) * 2017-12-01 2020-06-29 Seattle Genetics Inc Cd47 antibodies and uses thereof for treating cancer
EP3802599B1 (en) * 2018-06-03 2023-12-20 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
SG11202013248YA (en) * 2018-07-31 2021-02-25 Amgen Inc Pharmaceutical formulations of masked antibodies
TW202112801A (zh) * 2019-06-05 2021-04-01 美商西雅圖遺傳學公司 純化遮蔽抗體之方法
TW202112354A (zh) * 2019-06-05 2021-04-01 美商西雅圖遺傳學公司 遮蔽抗體調配物
JP2022548310A (ja) * 2019-09-23 2022-11-17 シートムエックス セラピューティクス，インコーポレイテッド 抗ｃｄ４７抗体、活性化可能抗ｃｄ４７抗体、およびその使用方法

Also Published As

Publication number Publication date
KR20240111823A (ko) 2024-07-17
WO2023072177A1 (en) 2023-05-04
EP4423138A1 (en) 2024-09-04
EP4423138A4 (en) 2026-03-04
TW202334216A (zh) 2023-09-01
AU2022376756A1 (en) 2024-05-09
US20240417463A1 (en) 2024-12-19
WO2023070353A1 (en) 2023-05-04
CN118434769A (zh) 2024-08-02
CA3235611A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
JP7678841B2 (ja) 抗ｃｔｌａ４抗体ならびにその作製及び使用方法
US20250215079A1 (en) Antibodies specifically binding pd-1, tim-3 or pd-1 and tim-3 and their uses
NL2017267B1 (en) Anti-pd-1 antibodies
TW202241507A (zh) Psma結合蛋白及其用途
WO2023072177A1 (en) Anti-cd47 antibodies and methods of use thereof
KR20250130296A (ko) 항-ccr8 항체 및 이의 용도
JP2024542914A (ja) ヒトｃｘｃｌ１６抗体およびその使用
BR122023018935B1 (pt) Anticorpo, polinucleotídeo, vetor, célula hospedeira bacteriana, método de produção de um anticorpo, composição farmacêutica e uso do anticorpo

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251021